Health and Fitness Health and Fitness
Thu, January 24, 2013
Wed, January 23, 2013
Tue, January 22, 2013
Mon, January 21, 2013
Fri, January 18, 2013
Thu, January 17, 2013
Wed, January 16, 2013
Tue, January 15, 2013
Mon, January 14, 2013
Fri, January 11, 2013
Thu, January 10, 2013
Wed, January 9, 2013
Tue, January 8, 2013
[ Tue, Jan 08th 2013 ] - Market Wire
Cambridge Heart Provides Update
Mon, January 7, 2013
Sun, January 6, 2013
Fri, January 4, 2013
Thu, January 3, 2013
Wed, January 2, 2013
Mon, December 31, 2012
Fri, December 28, 2012
Thu, December 27, 2012
Wed, December 26, 2012
[ Wed, Dec 26th 2012 ] - Market Wire
30 p.m. ET
Mon, December 24, 2012
Fri, December 21, 2012
Thu, December 20, 2012

Levi &;; Korsinsky Notifies Investors With Losses on Their Investment in Abiomed, Inc. of Class Action Lawsuit and th


//health-fitness.news-articles.net/content/2013/ .. -abiomed-inc-of-class-action-lawsuit-and-th.html
Published in Health and Fitness on Tuesday, January 8th 2013 at 15:00 GMT by Market Wire   Print publication without navigation


January 08, 2013 17:48 ET

UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors With Losses on Their Investment in Abiomed, Inc. of Class Action Lawsuit and the Deadline of January 15, 2013 to Seek a Lead Plaintiff Position

NEW YORK, NY--(Marketwire - Jan 8, 2013) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Abiomed, Inc. ("Abiomed" or the "Company") (NYSE: [ ABMD ]) stock between August 5, 2011 and October 31, 2012.

For more information, click here: [ http://zlk.9nl.com/abiomed-abmd ]. 

The complaint alleges that, throughout the Class Period, Abiomed made materially misleading statements regarding the Company's financial strength and prospects. In particular, it is alleged that positive statements concerning the Company were misleading because the United States Food and Drug Administration ("FDA") repeatedly warned Abiomed that its promotional materials contained inappropriate claims regarding its Impella 2.5 catheter and suggested improper off-label uses. Abiomed repeatedly assured investors that they had addressed the FDA's concerns and that the matter was resolved.

On November 1, 2012, Abiomed disclosed that the Department of Justice had initiated an investigation "focused on the Company's marketing and labeling of the Impella 2.5." On this news, shares of Abiomed's stock fell from $19.82 per share on October 31, 2012 to close at $13.61 on November 1, 2012.

If you suffered a loss in Abiomed you have until January 15, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [ jlevi@zlk.com ] or by telephone at (877) 363-5972, or visit [ http://zlk.9nl.com/abiomed-abmd ].

Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.



Publication Contributing Sources